Just What We Were Looking For: Roche Pays €70m For Preclinical Anti-CD25 Asset

 
• By Eleanor Malone

Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics. Roche sees combo future for Tusk’s cancer immunotherapy with its own portfolio. Total deal value could reach €655m.

Choosing the key to success from hanging keys concept for aspirations, achievement and incentive
Roche hopes Tusk holds the Treg depletion key • Source: Shutterstock

More from Immuno-oncology

More from Anticancer